The Global Cell Viability Assays Market size is expected to reach $2.5 billion by 2028, rising at a market growth of 9.7% CAGR during the forecast period.
Cell viability is used to measure the proportion of healthy and live cells in a population, and viability assays are done after the injection of an experimental substance to check the overall health and survival rate of the cells. In addition, cell viability assays are performed to check a drug"s efficiency, safety, and therapeutic abilities before it can be launched commercially in the market.
Studies related to viability are also carried out to determine the effectiveness of the cryopreservation techniques, cell culture techniques, and the toxicity of the experimental substance. The assays to measure cellular proliferation, and cytotoxicity are widely utilized to supervise the response of and health of the cultural cells when they are treated with various stimuli.
The type and number of cells with the expected result decide the proper technique for the assay method. The cell proliferation assay is the most suitable option to monitor the number of cellular divisions, DNA synthesis, number of cells, and metabolic activity. Calcein AM and trypan blue are the viability dyes used for cell counting and can also provide both the rate of proliferation and viable cell percentage.
Cell-based assays are generally used for collecting screening of compounds to evaluate if the test molecules have effects on cell proliferation or if they show direct cytotoxic impacts that may lead to cell death. In addition, cell-based assays are often used to measure the binding of receptors and various signal transduction events, which may involve the expression of genetic reporters, monitoring organelle functions, or cellular component’s movement.
The major strategies followed by the market participants are Product Launches. Based on the Analysis presented in the Cardinal matrix; Thermo Fisher Scientific, Inc. is the forerunner in the Cell Viability Assays Market. Companies such as Becton, Dickinson and Company, Merck KGaA, Bio-Rad Laboratories, Inc. are some of the key innovators in Cell Viability Assays Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Bio-Rad Laboratories Inc., Merck KGaA, Becton, Dickinson and Company, PerkinElmer Inc., Promega Corporation, Biotium, Creative Bioarray, and Abcam Plc.
Cell viability is used to measure the proportion of healthy and live cells in a population, and viability assays are done after the injection of an experimental substance to check the overall health and survival rate of the cells. In addition, cell viability assays are performed to check a drug"s efficiency, safety, and therapeutic abilities before it can be launched commercially in the market.
Studies related to viability are also carried out to determine the effectiveness of the cryopreservation techniques, cell culture techniques, and the toxicity of the experimental substance. The assays to measure cellular proliferation, and cytotoxicity are widely utilized to supervise the response of and health of the cultural cells when they are treated with various stimuli.
The type and number of cells with the expected result decide the proper technique for the assay method. The cell proliferation assay is the most suitable option to monitor the number of cellular divisions, DNA synthesis, number of cells, and metabolic activity. Calcein AM and trypan blue are the viability dyes used for cell counting and can also provide both the rate of proliferation and viable cell percentage.
Cell-based assays are generally used for collecting screening of compounds to evaluate if the test molecules have effects on cell proliferation or if they show direct cytotoxic impacts that may lead to cell death. In addition, cell-based assays are often used to measure the binding of receptors and various signal transduction events, which may involve the expression of genetic reporters, monitoring organelle functions, or cellular component’s movement.
COVID-19 Impact Analysis
From development & support to planning the medicine supply chain, the biotech and pharmaceutical companies are working jointly with the governments to address the COVID-19 pandemic. For example, many commonly used drugs like hydroxychloroquine have seen a sharp rise in the demand for COVID-19 management. The high demand for these drugs has given enormous opportunities for manufacturers of COVID-19 management drugs. In addition, the pharmaceutical and biotechnological companies are expected to see a sharp rise due to the rising demand for vaccines and treatment drugs for novel coronavirus, which will boost the market for cell viability assays.Market Growth Factors
Increase Access To Funding And Rise Of The Health Care Industry
The increasing amount and size of investments in the healthcare sector by the government of various countries are one of the primary factors boosting the market’s growth. Due to their fast economic development and increasing healthcare cost, many developing nations will have great access to the top-notch healthcare system. The rapid increase of the healthcare sector in various countries can be assed by the rising increase in per-capita spending on healthcare and rising demand for quality and affordable healthcare services. With the rising healthcare sector and increasing funding, market for cell viability assays will propel.Rising Cases Of Infectious And Chronic Disease
The cases of chronic diseases are increasing owing to the changing lifestyles and the increasing old age population, increasing obesity levels, easy & broad availability of tobacco, and urbanization. According to the United Nations, every three out of five deaths are related to four major non-communicable diseases (NCDs), which are diabetes, cardiovascular disease, chronic lung disease, and cancer. The management and prevention of NCDs have become a priority globally due to the rising burden of NCDs, especially in low-income countries. The growing incidences and frequency of infectious and chronic diseases are aiding the cell viability assay market to develop.Market Restraining Factor
The Unavailability Of Healthcare Professionals
The shortage of healthcare professionals is due to the investments in the training and education of healthcare workers in many countries. Also, the mismatch in the employment and education policies concerning the healthcare system and the population requirement is a significant factor. The situation worsens due to difficulties deploying healthcare workers in remote, underserved, and rural areas. Additionally, there is an increase in the migration of health workers, which may further increase the shortage, especially in low and lower-middle-income nations.Product Outlook
Based on the product, the cell viability assays market is segmented into consumables and instrument. Because pharmaceutical companies perform research & development with instruments like liquid chromatographers, nuclear resonance (NMR) spectrometers and gas chromatographer, which significantly increase the development and research cycles, and bring beneficial drugs to the market at a faster rate. Instrumental methods for the analysis of the cell viability gives significant advantages over manual ones.
Application Outlook
On the basis of application, the cell viability assays market is classified into drug discovery & development, stem cell research and diagnostics. The drug discovery & development segment recorded a considerable growth rate in the cell viability assays market in 2021. This is because the cell viability assay plays an essential role in various stages of drug development and discovery because of its adaptability, versatility, and flexibility. Cell viability is primarily used to assess the response of the cells against a drug or a chemical compound during the drug discovery and development process.End-user Outlook
By end user, the cell viability assays market is bifurcated into Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs, Academic & Research Institutes and Diagnostic Labs. The biopharmaceutical & pharmaceutical companies segment procured the highest growth rate in the cell viability assays market in 2021. This is attributable from the increasing usage of viability assays in pharmaceuticals to assess the influence of the developed agents’ cells. Researchers employ various cells to determine the effect of the developed treatment, which often targets cancer tumors.Regional Outlook
Region-wise, the cell viability assays market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region led the cell viability assays market by generating maximum revenue share in 2021. The market is expanding in this region because of the introduction of various government schemes, the rising cases of chronic diseases like cancer, and the presence of high-quality infrastructure for laboratory and clinical research in the region. There is also a lean towards stem cell-based research, which further opens new treatment opportunities.The Cardinal Matrix - Cell Viability Assays Market Competition Analysis
The major strategies followed by the market participants are Product Launches. Based on the Analysis presented in the Cardinal matrix; Thermo Fisher Scientific, Inc. is the forerunner in the Cell Viability Assays Market. Companies such as Becton, Dickinson and Company, Merck KGaA, Bio-Rad Laboratories, Inc. are some of the key innovators in Cell Viability Assays Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Bio-Rad Laboratories Inc., Merck KGaA, Becton, Dickinson and Company, PerkinElmer Inc., Promega Corporation, Biotium, Creative Bioarray, and Abcam Plc.
Recent Strategies Deployed in Cell Viability Assays Market
Partnerships, Collaborations and Agreements:
- Mar-2022: Promega came into an agreement with FUJIFILM Cellular Dynamics, a leader in providing human iPSC technologies. Under this agreement, the companies aimed to expedite the development of a new assay for drug discovery.
- Nov-2021: Thermo Fisher entered into an agreement with Cellenion, a BICO company. Through this agreement, the companies aimed to accelerate single-cell proteomics analyses with the integration of Cellenion’s proteoCHIPTM and cellenONE into TMT multiplexing technologies and Orbitrap Orbitrap mass spectrometers of Thermo Fisher. In addition, this integration would allow the companies to offer complete solutions ranging from automated sample preparation and single-cell isolation to mass spectrometry)-based proteomics analysis on single cells.
- Jun-2021: Bio-Rad Laboratories agreed with Seegene, a leading biotechnology business. Following this agreement, Bio-Rad aimed to leverage the capabilities of Seegene to accelerate its penetration within the United States market by receiving FDA approvals for its clinical assays.
Product Launches and Product Expansions:
- Sep-2022: PerkinElmer, Inc. unveiled Cellaca PLX Image Cytometry System, a platform that enables researchers to test Critical Quality Attributes of cell samples in a single automated workflow. Through this launch, PerkinElmer would benefit researchers working in the field of CAR-T cell therapy and required to design phenotyping of immune cells for downstream processes.
- Aug-2022: Thermo Fisher Scientific released Enhanced Applied Biosystems HIV-1 Genotyping Kit. The newly launched kit aligns with the previously launched Applied Biosystems MagMAX Viral/Pathogen Nucleic Acid Isolation Kit for HIV-1 Blood Spots. The product helps labs with an advanced tool for drug resistance surveillance of HIV mutations to antiretroviral therapeutic inhibitors.
- Mar-2022: Thermo Fisher released Gibco CTS Xenon Electroporation System, an electroporation system for cell therapy development. The product allows gene modification without utilizing traditional viral vectors.
- Mar-2022: BD unveiled the BD Rhapsody TCR/BCR Multiomic Assay, a range of reagents. Through this launch, the company aimed to offer a solution to researchers to simply as well as comprehensively evaluate key cells within the immune system. Moreover, it would help in the advancement of immuno-oncology, autoimmune disorders, and infectious diseases.
- Aug-2021: BD released BD COR PX/GX System, a fully automated high-throughput diagnostic system. Through this launch, the company aimed to redefine the concept of automation in molecular testing of infectious diseases throughout key laboratories as well as other centralized laboratories across the United States.
- Aug-2020: Promega launched the Promega Limit Dx SARS-CoV-2 Immunoassay, a serological antibody test for COVID-19. This in vitro diagnostic test aimed to offer a PPA sensitivity of 93.5% while being utilized and evaluated with samples from patients with diverse disease levels as well as 100% sensitivity within hospitalized patients.
Acquisitions and Mergers:
- Feb-2022: BD took over Cytognos, a Biotech company. Through this acquisition, the company aimed to expedite the strategy of BD to help in the management of chronic diseases by expanding its offerings, which include immune assessment tests, blood cancer diagnostics, and informatics with the aim to address the demands of clinicians, patients, and care providers.
- May-2021: PerkinElmer took over Nexcelom Bioscience, a Massachusetts-based biotechnology company. Under this acquisition, the integration would broaden PerkinElmer"s efforts to support the government, academic, and biopharmaceutical organizations in developing their comprehensive workflows and help efforts to boost time to market and time to target other beneficial therapies.
- Feb-2021: Thermo Fisher Scientific took over Cell Sorting Technology from Propel Labs, a biotechnology instrumentation company. Through this acquisition, Thermo Fisher strengthens its cell therapy research and cell analysis business with the flow cytometry expertise of Propel Labs, engineering strength, and R&D abilities.
- Apr-2020: Bio-Rad Laboratories took over Celsee, an instruments and consumables provider. With this acquisition, the company aimed to expand its reach throughout the world in order to meet the rising demands of customers for single-cell analysis and precision medicine in order to offer improved insight into the disease along with its diagnosis as well as treatment.
Geographical Expansions:
- Jun-2021: Bio-Rad Laboratories agreed with Seegene, a leading biotechnology business. Following this agreement, Bio-Rad aimed to leverage the capabilities of Seegene to accelerate its penetration within the United States market by receiving FDA approvals for its clinical assays.
Scope of the Study
By Product
- Consumables
- Reagents & Assay Kits
- Luminometric Assays
- Dye Exclusion Assays
- Colorimetric Assays
- Fluorometric Assays
- Microplates
- Reagents & Assay Kits
- Instruments
- Spectrophotometer
- Microscopy
- Cell Imaging & Analysis System
- Flow Cytometry
- Others
By End-user
- Biopharmaceutical & Pharmaceutical Companies
- CROs & CMOs
- Academic & Research Institutes
- Diagnostic Labs
By Application
- Stem Cell Research
- Drug Discovery & Development
- Diagnostics
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories Inc.
- Merck KGaA
- Becton, Dickinson and Company
- PerkinElmer Inc.
- Promega Corporation
- Biotium
- Creative Bioarray
- Abcam Plc
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Cell Viability Assays Market, by Product
1.4.2 Global Cell Viability Assays Market, by End User
1.4.3 Global Cell Viability Assays Market, by Application
1.4.4 Global Cell Viability Assays Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and Scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
Chapter 4. Global Cell Viability Assays Market by Product
4.1 Global Consumables Market by Region
4.2 Global Cell Viability Assays Market by Consumables Type
4.2.1 Global Reagents & Assay Kits Market by Region
4.2.2 Global Cell Viability Assays Market by Reagents & Assay Kits Type
4.2.2.1 Global Luminometric Assays Market by Region
4.2.2.2 Global Dye Exclusion Assays Market by Region
4.2.2.3 Global Colorimetric Assays Market by Region
4.2.2.4 Global Fluorometric Assays Market by Region
4.2.3 Global Microplates Market by Region
4.3 Global Instruments Market by Region
4.4 Global Cell Viability Assays Market by Instruments Type
4.4.1 Global Spectrophotometer Market by Region
4.4.2 Global Microscopy Market by Region
4.4.3 Global Cell Imaging & Analysis System Market by Region
4.4.4 Global Flow Cytometry Market by Region
4.4.5 Global Others Market by Region
Chapter 5. Global Cell Viability Assays Market by End-user
5.1 Global Biopharmaceutical & Pharmaceutical Companies Market by Region
5.2 Global CROs & CMOs Market by Region
5.3 Global Academic & Research Institutes Market by Region
5.4 Global Diagnostic Labs Market by Region
Chapter 6. Global Cell Viability Assays Market by Application
6.1 Global Stem Cell Research Market by Region
6.2 Global Drug Discovery & Development Market by Region
6.3 Global Diagnostics Market by Region
Chapter 7. Global Cell Viability Assays Market by Region
7.1 North America Cell Viability Assays Market
7.1.1 North America Cell Viability Assays Market by Product
7.1.1.1 North America Consumables Market by Country
7.1.1.2 North America Cell Viability Assays Market by Consumables Type
7.1.1.2.1 North America Reagents & Assay Kits Market by Country
7.1.1.2.2 North America Cell Viability Assays Market by Reagents & Assay Kits Type
7.1.1.2.2.1 North America Luminometric Assays Market by Country
7.1.1.2.2.2 North America Dye Exclusion Assays Market by Country
7.1.1.2.2.3 North America Colorimetric Assays Market by Country
7.1.1.2.2.4 North America Fluorometric Assays Market by Country
7.1.1.2.3 North America Microplates Market by Country
7.1.1.3 North America Instruments Market by Country
7.1.1.4 North America Cell Viability Assays Market by Instruments Type
7.1.1.4.1 North America Spectrophotometer Market by Country
7.1.1.4.2 North America Microscopy Market by Country
7.1.1.4.3 North America Cell Imaging & Analysis System Market by Country
7.1.1.4.4 North America Flow Cytometry Market by Country
7.1.1.4.5 North America Others Market by Country
7.1.2 North America Cell Viability Assays Market by End-user
7.1.2.1 North America Biopharmaceutical & Pharmaceutical Companies Market by Country
7.1.2.2 North America CROs & CMOs Market by Country
7.1.2.3 North America Academic & Research Institutes Market by Country
7.1.2.4 North America Diagnostic Labs Market by Country
7.1.3 North America Cell Viability Assays Market by Application
7.1.3.1 North America Stem Cell Research Market by Country
7.1.3.2 North America Drug Discovery & Development Market by Country
7.1.3.3 North America Diagnostics Market by Country
7.1.4 North America Cell Viability Assays Market by Country
7.1.4.1 US Cell Viability Assays Market
7.1.4.1.1 US Cell Viability Assays Market by Product
7.1.4.1.1.1 US Cell Viability Assays Market by Consumables Type
7.1.4.1.1.2 US Cell Viability Assays Market by Instruments Type
7.1.4.1.2 US Cell Viability Assays Market by End-user
7.1.4.1.3 US Cell Viability Assays Market by Application
7.1.4.2 Canada Cell Viability Assays Market
7.1.4.2.1 Canada Cell Viability Assays Market by Product
7.1.4.2.1.1 Canada Cell Viability Assays Market by Consumables Type
7.1.4.2.1.2 Canada Cell Viability Assays Market by Instruments Type
7.1.4.2.2 Canada Cell Viability Assays Market by End-user
7.1.4.2.3 Canada Cell Viability Assays Market by Application
7.1.4.3 Mexico Cell Viability Assays Market
7.1.4.3.1 Mexico Cell Viability Assays Market by Product
7.1.4.3.1.1 Mexico Cell Viability Assays Market by Consumables Type
7.1.4.3.1.2 Mexico Cell Viability Assays Market by Instruments Type
7.1.4.3.2 Mexico Cell Viability Assays Market by End-user
7.1.4.3.3 Mexico Cell Viability Assays Market by Application
7.1.4.4 Rest of North America Cell Viability Assays Market
7.1.4.4.1 Rest of North America Cell Viability Assays Market by Product
7.1.4.4.1.1 Rest of North America Cell Viability Assays Market by Consumables Type
7.1.4.4.1.2 Rest of North America Cell Viability Assays Market by Instruments Type
7.1.4.4.2 Rest of North America Cell Viability Assays Market by End-user
7.1.4.4.3 Rest of North America Cell Viability Assays Market by Application
7.2 Europe Cell Viability Assays Market
7.2.1 Europe Cell Viability Assays Market by Product
7.2.1.1 Europe Consumables Market by Country
7.2.1.2 Europe Cell Viability Assays Market by Consumables Type
7.2.1.2.1 Europe Reagents & Assay Kits Market by Country
7.2.1.2.2 Europe Cell Viability Assays Market by Reagents & Assay Kits Type
7.2.1.2.2.1 Europe Luminometric Assays Market by Country
7.2.1.2.2.2 Europe Dye Exclusion Assays Market by Country
7.2.1.2.2.3 Europe Colorimetric Assays Market by Country
7.2.1.2.2.4 Europe Fluorometric Assays Market by Country
7.2.1.2.3 Europe Microplates Market by Country
7.2.1.3 Europe Instruments Market by Country
7.2.1.4 Europe Cell Viability Assays Market by Instruments Type
7.2.1.4.1 Europe Spectrophotometer Market by Country
7.2.1.4.2 Europe Microscopy Market by Country
7.2.1.4.3 Europe Cell Imaging & Analysis System Market by Country
7.2.1.4.4 Europe Flow Cytometry Market by Country
7.2.1.4.5 Europe Others Market by Country
7.2.2 Europe Cell Viability Assays Market by End-user
7.2.2.1 Europe Biopharmaceutical & Pharmaceutical Companies Market by Country
7.2.2.2 Europe CROs & CMOs Market by Country
7.2.2.3 Europe Academic & Research Institutes Market by Country
7.2.2.4 Europe Diagnostic Labs Market by Country
7.2.3 Europe Cell Viability Assays Market by Application
7.2.3.1 Europe Stem Cell Research Market by Country
7.2.3.2 Europe Drug Discovery & Development Market by Country
7.2.3.3 Europe Diagnostics Market by Country
7.2.4 Europe Cell Viability Assays Market by Country
7.2.4.1 Germany Cell Viability Assays Market
7.2.4.1.1 Germany Cell Viability Assays Market by Product
7.2.4.1.1.1 Germany Cell Viability Assays Market by Consumables Type
7.2.4.1.1.2 Germany Cell Viability Assays Market by Instruments Type
7.2.4.1.2 Germany Cell Viability Assays Market by End-user
7.2.4.1.3 Germany Cell Viability Assays Market by Application
7.2.4.2 UK Cell Viability Assays Market
7.2.4.2.1 UK Cell Viability Assays Market by Product
7.2.4.2.1.1 UK Cell Viability Assays Market by Consumables Type
7.2.4.2.1.2 UK Cell Viability Assays Market by Instruments Type
7.2.4.2.2 UK Cell Viability Assays Market by End-user
7.2.4.2.3 UK Cell Viability Assays Market by Application
7.2.4.3 France Cell Viability Assays Market
7.2.4.3.1 France Cell Viability Assays Market by Product
7.2.4.3.1.1 France Cell Viability Assays Market by Consumables Type
7.2.4.3.1.2 France Cell Viability Assays Market by Instruments Type
7.2.4.3.2 France Cell Viability Assays Market by End-user
7.2.4.3.3 France Cell Viability Assays Market by Application
7.2.4.4 Russia Cell Viability Assays Market
7.2.4.4.1 Russia Cell Viability Assays Market by Product
7.2.4.4.1.1 Russia Cell Viability Assays Market by Consumables Type
7.2.4.4.1.2 Russia Cell Viability Assays Market by Instruments Type
7.2.4.4.2 Russia Cell Viability Assays Market by End-user
7.2.4.4.3 Russia Cell Viability Assays Market by Application
7.2.4.5 Spain Cell Viability Assays Market
7.2.4.5.1 Spain Cell Viability Assays Market by Product
7.2.4.5.1.1 Spain Cell Viability Assays Market by Consumables Type
7.2.4.5.1.2 Spain Cell Viability Assays Market by Instruments Type
7.2.4.5.2 Spain Cell Viability Assays Market by End-user
7.2.4.5.3 Spain Cell Viability Assays Market by Application
7.2.4.6 Italy Cell Viability Assays Market
7.2.4.6.1 Italy Cell Viability Assays Market by Product
7.2.4.6.1.1 Italy Cell Viability Assays Market by Consumables Type
7.2.4.6.1.2 Italy Cell Viability Assays Market by Instruments Type
7.2.4.6.2 Italy Cell Viability Assays Market by End-user
7.2.4.6.3 Italy Cell Viability Assays Market by Application
7.2.4.7 Rest of Europe Cell Viability Assays Market
7.2.4.7.1 Rest of Europe Cell Viability Assays Market by Product
7.2.4.7.1.1 Rest of Europe Cell Viability Assays Market by Consumables Type
7.2.4.7.1.2 Rest of Europe Cell Viability Assays Market by Instruments Type
7.2.4.7.2 Rest of Europe Cell Viability Assays Market by End-user
7.2.4.7.3 Rest of Europe Cell Viability Assays Market by Application
7.3 Asia Pacific Cell Viability Assays Market
7.3.1 Asia Pacific Cell Viability Assays Market by Product
7.3.1.1 Asia Pacific Consumables Market by Country
7.3.1.2 Asia Pacific Cell Viability Assays Market by Consumables Type
7.3.1.2.1 Asia Pacific Reagents & Assay Kits Market by Country
7.3.1.2.2 Asia Pacific Cell Viability Assays Market by Reagents & Assay Kits Type
7.3.1.2.2.1 Asia Pacific Luminometric Assays Market by Country
7.3.1.2.2.2 Asia Pacific Dye Exclusion Assays Market by Country
7.3.1.2.2.3 Asia Pacific Colorimetric Assays Market by Country
7.3.1.2.2.4 Asia Pacific Fluorometric Assays Market by Country
7.3.1.2.3 Asia Pacific Microplates Market by Country
7.3.1.3 Asia Pacific Instruments Market by Country
7.3.1.4 Asia Pacific Cell Viability Assays Market by Instruments Type
7.3.1.4.1 Asia Pacific Spectrophotometer Market by Country
7.3.1.4.2 Asia Pacific Microscopy Market by Country
7.3.1.4.3 Asia Pacific Cell Imaging & Analysis System Market by Country
7.3.1.4.4 Asia Pacific Flow Cytometry Market by Country
7.3.1.4.5 Asia Pacific Others Market by Country
7.3.2 Asia Pacific Cell Viability Assays Market by End-user
7.3.2.1 Asia Pacific Biopharmaceutical & Pharmaceutical Companies Market by Country
7.3.2.2 Asia Pacific CROs & CMOs Market by Country
7.3.2.3 Asia Pacific Academic & Research Institutes Market by Country
7.3.2.4 Asia Pacific Diagnostic Labs Market by Country
7.3.3 Asia Pacific Cell Viability Assays Market by Application
7.3.3.1 Asia Pacific Stem Cell Research Market by Country
7.3.3.2 Asia Pacific Drug Discovery & Development Market by Country
7.3.3.3 Asia Pacific Diagnostics Market by Country
7.3.4 Asia Pacific Cell Viability Assays Market by Country
7.3.4.1 China Cell Viability Assays Market
7.3.4.1.1 China Cell Viability Assays Market by Product
7.3.4.1.1.1 China Cell Viability Assays Market by Consumables Type
7.3.4.1.1.2 China Cell Viability Assays Market by Instruments Type
7.3.4.1.2 China Cell Viability Assays Market by End-user
7.3.4.1.3 China Cell Viability Assays Market by Application
7.3.4.2 Japan Cell Viability Assays Market
7.3.4.2.1 Japan Cell Viability Assays Market by Product
7.3.4.2.1.1 Japan Cell Viability Assays Market by Consumables Type
7.3.4.2.1.2 Japan Cell Viability Assays Market by Instruments Type
7.3.4.2.2 Japan Cell Viability Assays Market by End-user
7.3.4.2.3 Japan Cell Viability Assays Market by Application
7.3.4.3 India Cell Viability Assays Market
7.3.4.3.1 India Cell Viability Assays Market by Product
7.3.4.3.1.1 India Cell Viability Assays Market by Consumables Type
7.3.4.3.1.2 India Cell Viability Assays Market by Instruments Type
7.3.4.3.2 India Cell Viability Assays Market by End-user
7.3.4.3.3 India Cell Viability Assays Market by Application
7.3.4.4 South Korea Cell Viability Assays Market
7.3.4.4.1 South Korea Cell Viability Assays Market by Product
7.3.4.4.1.1 South Korea Cell Viability Assays Market by Consumables Type
7.3.4.4.1.2 South Korea Cell Viability Assays Market by Instruments Type
7.3.4.4.2 South Korea Cell Viability Assays Market by End-user
7.3.4.4.3 South Korea Cell Viability Assays Market by Application
7.3.4.5 Singapore Cell Viability Assays Market
7.3.4.5.1 Singapore Cell Viability Assays Market by Product
7.3.4.5.1.1 Singapore Cell Viability Assays Market by Consumables Type
7.3.4.5.1.2 Singapore Cell Viability Assays Market by Instruments Type
7.3.4.5.2 Singapore Cell Viability Assays Market by End-user
7.3.4.5.3 Singapore Cell Viability Assays Market by Application
7.3.4.6 Malaysia Cell Viability Assays Market
7.3.4.6.1 Malaysia Cell Viability Assays Market by Product
7.3.4.6.1.1 Malaysia Cell Viability Assays Market by Consumables Type
7.3.4.6.1.2 Malaysia Cell Viability Assays Market by Instruments Type
7.3.4.6.2 Malaysia Cell Viability Assays Market by End-user
7.3.4.6.3 Malaysia Cell Viability Assays Market by Application
7.3.4.7 Rest of Asia Pacific Cell Viability Assays Market
7.3.4.7.1 Rest of Asia Pacific Cell Viability Assays Market by Product
7.3.4.7.1.1 Rest of Asia Pacific Cell Viability Assays Market by Consumables Type
7.3.4.7.1.2 Rest of Asia Pacific Cell Viability Assays Market by Instruments Type
7.3.4.7.2 Rest of Asia Pacific Cell Viability Assays Market by End-user
7.3.4.7.3 Rest of Asia Pacific Cell Viability Assays Market by Application
7.4 LAMEA Cell Viability Assays Market
7.4.1 LAMEA Cell Viability Assays Market by Product
7.4.1.1 LAMEA Consumables Market by Country
7.4.1.2 LAMEA Cell Viability Assays Market by Consumables Type
7.4.1.2.1 LAMEA Reagents & Assay Kits Market by Country
7.4.1.2.2 LAMEA Cell Viability Assays Market by Reagents & Assay Kits Type
7.4.1.2.2.1 LAMEA Luminometric Assays Market by Country
7.4.1.2.2.2 LAMEA Dye Exclusion Assays Market by Country
7.4.1.2.2.3 LAMEA Colorimetric Assays Market by Country
7.4.1.2.2.4 LAMEA Fluorometric Assays Market by Country
7.4.1.2.3 LAMEA Microplates Market by Country
7.4.1.3 LAMEA Instruments Market by Country
7.4.1.4 LAMEA Cell Viability Assays Market by Instruments Type
7.4.1.4.1 LAMEA Spectrophotometer Market by Country
7.4.1.4.2 LAMEA Microscopy Market by Country
7.4.1.4.3 LAMEA Cell Imaging & Analysis System Market by Country
7.4.1.4.4 LAMEA Flow Cytometry Market by Country
7.4.1.4.5 LAMEA Others Market by Country
7.4.2 LAMEA Cell Viability Assays Market by End-user
7.4.2.1 LAMEA Biopharmaceutical & Pharmaceutical Companies Market by Country
7.4.2.2 LAMEA CROs & CMOs Market by Country
7.4.2.3 LAMEA Academic & Research Institutes Market by Country
7.4.2.4 LAMEA Diagnostic Labs Market by Country
7.4.3 LAMEA Cell Viability Assays Market by Application
7.4.3.1 LAMEA Stem Cell Research Market by Country
7.4.3.2 LAMEA Drug Discovery & Development Market by Country
7.4.3.3 LAMEA Diagnostics Market by Country
7.4.4 LAMEA Cell Viability Assays Market by Country
7.4.4.1 Brazil Cell Viability Assays Market
7.4.4.1.1 Brazil Cell Viability Assays Market by Product
7.4.4.1.1.1 Brazil Cell Viability Assays Market by Consumables Type
7.4.4.1.1.2 Brazil Cell Viability Assays Market by Instruments Type
7.4.4.1.2 Brazil Cell Viability Assays Market by End-user
7.4.4.1.3 Brazil Cell Viability Assays Market by Application
7.4.4.2 Argentina Cell Viability Assays Market
7.4.4.2.1 Argentina Cell Viability Assays Market by Product
7.4.4.2.1.1 Argentina Cell Viability Assays Market by Consumables Type
7.4.4.2.1.2 Argentina Cell Viability Assays Market by Instruments Type
7.4.4.2.2 Argentina Cell Viability Assays Market by End-user
7.4.4.2.3 Argentina Cell Viability Assays Market by Application
7.4.4.3 UAE Cell Viability Assays Market
7.4.4.3.1 UAE Cell Viability Assays Market by Product
7.4.4.3.1.1 UAE Cell Viability Assays Market by Consumables Type
7.4.4.3.1.2 UAE Cell Viability Assays Market by Instruments Type
7.4.4.3.2 UAE Cell Viability Assays Market by End-user
7.4.4.3.3 UAE Cell Viability Assays Market by Application
7.4.4.4 Saudi Arabia Cell Viability Assays Market
7.4.4.4.1 Saudi Arabia Cell Viability Assays Market by Product
7.4.4.4.1.1 Saudi Arabia Cell Viability Assays Market by Consumables Type
7.4.4.4.1.2 Saudi Arabia Cell Viability Assays Market by Instruments Type
7.4.4.4.2 Saudi Arabia Cell Viability Assays Market by End-user
7.4.4.4.3 Saudi Arabia Cell Viability Assays Market by Application
7.4.4.5 South Africa Cell Viability Assays Market
7.4.4.5.1 South Africa Cell Viability Assays Market by Product
7.4.4.5.1.1 South Africa Cell Viability Assays Market by Consumables Type
7.4.4.5.1.2 South Africa Cell Viability Assays Market by Instruments Type
7.4.4.5.2 South Africa Cell Viability Assays Market by End-user
7.4.4.5.3 South Africa Cell Viability Assays Market by Application
7.4.4.6 Nigeria Cell Viability Assays Market
7.4.4.6.1 Nigeria Cell Viability Assays Market by Product
7.4.4.6.1.1 Nigeria Cell Viability Assays Market by Consumables Type
7.4.4.6.1.2 Nigeria Cell Viability Assays Market by Instruments Type
7.4.4.6.2 Nigeria Cell Viability Assays Market by End-user
7.4.4.6.3 Nigeria Cell Viability Assays Market by Application
7.4.4.7 Rest of LAMEA Cell Viability Assays Market
7.4.4.7.1 Rest of LAMEA Cell Viability Assays Market by Product
7.4.4.7.1.1 Rest of LAMEA Cell Viability Assays Market by Consumables Type
7.4.4.7.1.2 Rest of LAMEA Cell Viability Assays Market by Instruments Type
7.4.4.7.2 Rest of LAMEA Cell Viability Assays Market by End-user
7.4.4.7.3 Rest of LAMEA Cell Viability Assays Market by Application
Chapter 8. Company Profiles
8.1 Thermo Fisher Scientific, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Product Launches and Product Expansions:
8.1.5.3 Acquisition and Mergers:
8.1.5.4 Geographical Expansions:
8.2 Agilent Technologies, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.3 Bio-Rad laboratories, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition and Mergers:
8.4 Becton, Dickinson and Company
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Product Launches and Product Expansions:
8.4.5.2 Acquisition and Mergers:
8.5 PerkinElmer, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Product Launches and Product Expansions:
8.5.5.2 Acquisition and Mergers:
8.6 Merck KGaA
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.7 Abcam plc
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expenses
8.8 Promega Corporation
8.8.1 Company Overview
8.8.2 Recent strategies and developments:
8.8.2.1 Partnerships, Collaborations, and Agreements:
8.8.2.2 Product Launches and Product Expansions:
8.9 Creative Bioarray
8.9.1 Company Overview
8.10. Biotium, Inc.
8.10.1 Company Overview
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories Inc.
- Merck KGaA
- Becton, Dickinson and Company
- PerkinElmer Inc.
- Promega Corporation
- Biotium
- Creative Bioarray
- Abcam Plc
Methodology
LOADING...
